Fulcrum Therapeutics (NASDAQ:FULC) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Fulcrum Therapeutics (NASDAQ:FULC) announced its quarterly earnings data on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.03), Zacks reports.

Fulcrum Therapeutics Stock Up 0.2 %

NASDAQ:FULC traded up $0.01 on Thursday, reaching $3.33. The company’s stock had a trading volume of 70,025 shares, compared to its average volume of 451,849. Fulcrum Therapeutics has a 12-month low of $2.86 and a 12-month high of $13.70. The stock has a 50 day moving average price of $4.13 and a 200 day moving average price of $4.62. The firm has a market cap of $179.35 million, a price-to-earnings ratio of -10.73 and a beta of 2.03.

Analyst Ratings Changes

Several research analysts have recently weighed in on FULC shares. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. HC Wainwright reissued a “neutral” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Wednesday. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.